JNJ vs REGN
By Alex · Tickerpine
Johnson & Johnson vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | REGN |
|---|---|---|
| Price | $263.81 | $805.02 |
| Market cap | $635.07B | $82.88B |
| P/E ratio | 40.0 | 19.9 |
| ROE | 20.02% | 14.04% |
| Profit margin | 16.20% | 27.87% |
| Revenue growth | 5.90% | 16.70% |
| Dividend yield | 2.03% | 0.47% |
| Beta | 0.21 | 0.15 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs REGN in plain English
- JNJ is the bigger company — about 7.7× the market cap of REGN.
- REGN is cheaper on earnings (P/E 19.9 vs 40.0).
- JNJ earns a higher return on equity (20% vs 14%).
- REGN is growing revenue faster (17% vs 6%).
- JNJ has the higher dividend yield (2.03% vs 0.47%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.